Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capricor TherapeuticsCAPR -0.05%37 Debt-to-Equity is 0.05 as of Mar. 2026, which is 25% above its 10-year median of 0.04. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Capricor Therapeutics ranks better than 72.02% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Capricor Therapeutics's Debt-to-Equity or its related term are showing as below:
CAPR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.47 Med: 0.04 Max: 283.8
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of Capricor Therapeutics was 283.80. The lowest was -3.47. And the median was 0.04.
CAPR's Debt-to-Equity is ranked better than 72.02% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs CAPR: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Capricor Therapeutics Debt-to-Equity Related Terms
Capricor Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Capricor Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAPR vs COAG, DMRA, MPLT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Capricor Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics (CAPR) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Capricor Therapeutics and its competitors. This is 25% above median its historical median of 0.04. According to the industry distribution chart, Capricor Therapeutics ranks #270 out of 965 companies in the Biotechnology industry, placing it in the top 28%.
Is Capricor Therapeutics' Debt-to-Equity too high?
Capricor Therapeutics' current Debt-to-Equity of 0.05 is 25% above median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. Capricor Therapeutics' value of 0.05 is 68.8% below this industry median. Based on the distribution chart, Capricor Therapeutics ranks #270 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Debt-to-Equity compare to COAG and DMRA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #270 out of 965 companies for Debt-to-Equity. This puts Capricor Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Capricor Therapeutics' value of 0.05 is 68.8% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Capricor Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Capricor Therapeutics's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Debt-to-Equity is 0.05, which is 25% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $19.12 — trading 292.6% above its estimated fair value. The current Debt-to-Equity is 0.05, which is 25% above median its 10-year median of 0.04 and 68.8% below the Biotechnology industry median of 0.16. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $19.12 is trading 292.6% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Debt-to-Equity: 0.05 (25% above median its 10-year median of 0.04)
GF Value™: $4.87 vs. price of $19.12 (292.6% above fair value)
Industry Position: 68.8% below the Biotechnology median (#270 of 965)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
